RSRuth L. Savage

Ruth L. Savage

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruth L. Savage has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Uncovering Pregnancy Exposures in Pharmacovigilance Case Report Databases: A Comprehensive Evaluation of the VigiBase Pregnancy Algorithm

    by Lovisa Sandberg, Sara Hedfors Vidlin, Levente K-Pápai, Ruth Savage, Boukje C. Raemaekers, Henric Taavola-Gustafsson, Annette Rudolph, Lucy Quirant, Tomas Bergvall, Magnus Wallberg, et al.

    Information on the safety of medicine use during pregnancy is limited at the time of marketing, making post-marketing surveillance essential. However, the lack of a specific indicator for pregnancy-related case reports within the international standard for transmission of individual case safety reports complicates the retrieval of such reports in pharmacovigilance databases. To address this, an algorithm to identify reports of exposures during pregnancy was developed in VigiBase, the World Health Organization global database of adverse event reports. We aimed to evaluate and characterise the VigiBase pregnancy algorithm. The rule-based algorithm uses multiple structured data elements in the International Council of Harmonisation (ICH) E2B transmission format that could potentially hold pregnancy-related information, to determine if a case report qualifies as a pregnancy case. Free text information is not considered. Three datasets were used for the evaluation. The "Full dataset" comprised deduplicated VigiBase data up to January 2023. The "Downsampled dataset" was a subsample of the Full dataset, adjusted to increase the prevalence of pregnancy reports by excluding individuals aged 45 years or older and male individuals aged 18 years or older, used to evaluate recall (i.e. sensitivity). The "Random dataset" was a straight random sample of the Full dataset, used to evaluate precision (i.e. positive predictive value). As a baseline for comparison, the Standardised Medical Dictionary for Regulatory Activities (MedDRA®) Query (SMQ) "Pregnancy and neonatal topics (narrow)" was used. To provide a gold standard for the evaluation, case reports were manually annotated as either "pregnancy case" or "non-pregnancy case", for all reports in the Downsampled dataset, and for the reports flagged as pregnancy cases by the algorithm or the SMQ baseline in the Random dataset. In the Downsampled dataset with 7874 annotated reports, 253 reports were annotated as pregnancy cases. Of those, the algorithm recalled 75% (95% confidence interval [CI] 69-80), increasing to 91% (95% CI 86-95) when restricting the analysis to reports adhering to the ICH E2B format. Preprocessing obstacles of incomplete mapping of specific pregnancy terms to MedDRA® led to most false negatives followed by pregnancy information confined to free text information. The SMQ baseline had a lower recall of 62% (95% CI 56-68). In the Random dataset with 30,000 reports, the algorithm flagged 344 reports, among which 316 were annotated as pregnancy cases, leading to a precision of 92% (95% CI 88-95). The main reasons for false positives were postpartum indications, non-pregnancy-specific events or information miscoded as pregnancy related. The SMQ baseline had a lower precision of 74% (95% CI 69-78). The VigiBase pregnancy algorithm demonstrates robust performance, highlighting its potential to facilitate pharmacovigilance related to pregnancy. Our evaluation establishes a valuable benchmark for future research and emphasises the need for global harmonisation of standards for reporting pregnancy exposures.


  • Open Access

    Diclofenac and the Risk of Rhabdomyolysis: Analysis of Publications and the WHO Global Pharmacovigilance Database

    by Mulugeta Russom, Yodit Fitsum, Abiel Abraham, Ruth L. Savage

    Background Diclofenac, a nonsteroidal anti-inflammatory drug, is not a documented cause of rhabdomyolysis in the Summaries of Product Characteristics held by major regulators. There are, however, eight published single case reports that associate rhabdomyolysis with diclofenac. Objective Triggered by a serious local case report, this study was conducted to evaluate the evidence for a causal association between diclofenac and rhabdomyolysis. Patients and Methods A descriptive analysis of rhabdomyolysis associated with diclofenac was conducted by mining data from the WHO Global Database of Individual Case Safety Reports, VigiBase, and published case reports. Results 70 eligible cases were retrieved from VigiBase. The median age was 56.5 years (range 1–90). Where reported precisely (26 reports), the median time to onset of rhabdomyolysis following administration of diclofenac was 3 days. In 20 cases, diclofenac was reported as a sole suspect and was solely administered in 14 of these. In 30 cases, rhabdomyolysis abated following withdrawal of diclofenac. Seven of these cases fulfilled the WHO-UMC case-causality assessment criteria for ‘probable’. Diclofenac was probably an indirect cause in another five reports where rhabdomyolysis ensued from injection-site necrosis. There were eight fatalities and intramuscular administration was over-represented in this group. In 27 patients taking lipid-lowering agents, the incidence of acute kidney injury with rhabdomyolysis was 62.9% compared with 37.1% for the whole cohort. Off-label use of diclofenac for minor or undiagnosed conditions was reported. Conclusion Currently available data suggests a causal link between diclofenac and rhabdomyolysis either directly or indirectly.


  • Open Access

    E-Learning in Pharmacovigilance: An Evaluation of Microlearning-Based Modules Developed by Uppsala Monitoring Centre

    by Anna Hegerius, Pia Caduff-Janosa, Ruth Savage, Johan Ellenius

    Introduction An increasing global need for pharmacovigilance training cannot be met with classroom courses alone. Several e-learning modules have been developed by Uppsala Monitoring Centre (UMC). With distance learners and technological challenges such as poor internet bandwidth to be considered, UMC opted for the microlearning approach based on small learning units connected to specific learning objectives. The aim of this study was to evaluate how this e-learning course was received. Methods The course was evaluated through usage data and the results of two user surveys, one for modules 1–4, signal detection and causality assessment, and the other for module 5, statistical reasoning and algorithms in pharmacovigilance. The evaluation model used was based on the Unified Theory of Acceptance and Use of Technology (UTAUT). A questionnaire was developed, divided into demographic profile, performance expectancy, effort expectancy, educational compatibility and behavioural intention. The two surveys were disseminated to 2067 learners for modules 1–4 and 1685 learners for module 5. Results Learners from 137 countries participated, predominantly from industry (36.6%), national pharmacovigilance centres (22.6%) and academia (16.3%). The overall satisfaction level was very high for all modules, with over 90% of the learners rating it as either ‘excellent’ or ‘good’. The majority were satisfied with the learning platform, the course content and the lesson duration. Most learners thought they would be able to apply the knowledge in practice. Almost 100% of the learners would recommend the modules to others and would also study future modules. Suggested improvements were an interactive forum, more practical examples in the lessons and practical exercises. Conclusion This e-learning course in pharmacovigilance based on microlearning was well received with a global coverage among relevant professional disciplines.


  • Open Access

    Suspected Hepatotoxicity With a Supercritical Carbon Dioxide Extract of Artemisia annua in Grapeseed Oil Used in New Zealand

    by Ruth L. Savage, Geraldine R. Hill, Joanne Barnes, Susan H. Kenyon, Michael V. Tatley

    A case series of hepatotoxicity associated with an extract of Artemisia annua L. was identified through the New Zealand spontaneous adverse drug reaction reporting system. A. annua extract, produced using a supercritical carbon dioxide extraction method and formulated with grapeseed oil, has been marketed in New Zealand as a natural product for joint health. As of 31 January 2019, the New Zealand Pharmacovigilance Centre had received 29 reports of hepatic adverse reactions occurring in patients taking A. annua extract in grapeseed oil. The case reports were assessed for patient and adverse reaction characteristics, patterns of A. annua extract use and causality (based on the WHO-UMC system for standardized case causality assessment). Patients were aged 47 to 93 years (median 67). Time to onset of hepatotoxicity from starting A. annua extract was 7 days to approximately 12 months in the 23 reports with this information. Nineteen of these reports indicated onset within 12 weeks. A. annua extract was the sole suspect medicine in 27 reports. A few patients had possible predisposing conditions. Twenty-seven patients were reported to have recovered or improved on stopping A. annua extract. Nine patients required hospital admission. The pattern of hepatic injury varied. Jaundice, often with pruritus and dark urine, was experienced by 16 patients. There was considerable consistency across case reports from various reporters. We assessed the case reports as a series using the Bradford Hill guidelines for causal inference and concluded that there was a safety signal of a causal association between the A. annua extract and hepatotoxicity sufficient to be communicated and investigated further.


  • Open Access

    Case Series Analysis of New Zealand Reports of Rapid Intense Potentiation of Warfarin by Roxithromycin

    by Ruth L. Savage, Michael V. Tatley

    We undertook an analysis of all the reports to the New Zealand Centre for Adverse Reactions Monitoring of a roxithromycin/warfarin interaction after two recent reports described intense rapid warfarin potentiation. The interaction was first published in 1995. Cytochrome P450 3A4 inhibition has been the proposed mechanism but has limited biologic plausibility. There are suggestions that the clinical significance of the interaction may be increased by severe illness, polypharmacy, renal dysfunction, older age and increased warfarin sensitivity.


  • Erratum: International Reports of Unexpected Low Plasma Concentrations of Dabigatran Suggest That More Frequent Measurements Will Add Value

    by Marilina Castellano, Michael V. Tatley, Ruth L. Savage

    It has been brought to the publisher's attention that the reference citations in [Table 1] were incorrect in the above article in Seminars in Thrombosis and Hemostasis, Volume 43, Number 6, 2017 (DOI: 10.1055/s-0037-1603361). The references cited in the table are provided below. The correct table appears on the next page. 5 Breuer L, Ringwald J, Schwab S, Köhrmann M. Ischemic stroke in an obese patient receiving dabigatran [letter]. N Engl JMed 2013;368(25):2440–2442 6 Douros A, Schlemm L, Bolbrinker J, Ebinger M, Kreutz R. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome [letter]. Thromb Haemost 2014;112(02):419–420 7 Sargento-Freitas J, Silva F, Pego J, Duque C, Cordeiro G, Cunha L. Cardioembolic stroke in a patient taking dabigatran etexilate: the first case report of clinical and pharmacologic resistance [letter]. J Neurol Sci 2014;346(1–2):348–349 8 Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y bypass surgery [letter]. J Cardiol Cases 2013;8:e49–e50

  • International Reports of Unexpected Low Plasma Concentrations of Dabigatran Suggest That More Frequent Measurements Will Add Value

    by Marilina Castellano, Michael V. Tatley, Ruth L. Savage

    We were interested to read the report by Chin[1] recently published in this journal, suggesting that some patients may benefit from dose adjustment of non–vitamin K antagonist oral anticoagulants (NOACs), otherwise referred to as direct oral anticoagulants (DOACs). We would like to report a small case series that provides evidence for selective dose adjustment and/or measurement of NOACs, in particular dabigatran. The World Health Organization (WHO) Global Database of Individual Case Safety Reports (“VigiBase”) holds reports of suspected adverse drug reactions collected worldwide through the WHO Program for International Drug Monitoring.[2] A previous investigation of reports of thromboembolic events associated with dabigatran in VigiBase[3] included a literature search, which identified four published case reports of dabigatran plasma concentrations below the expected “within therapy range” (representing the generally reported range of values identified in patients on such therapy in clinical trials). VigiBase was therefore searched for similar reports of low plasma concentrations. It is acknowledged, however, that the information provided in VigiBase is heterogeneous (i.e., it originates from multiple sources [different countries and types of reporters] and the amount of information given, as well as the likelihood that the medicine caused the adverse reaction, may vary from case to case). Two of the published reports and 12 additional reports of this unexpected effect were identified, originating from five countries. While specific target therapeutic ranges for dabigatran plasma concentrations have not been validated, “within therapy” ranges identifying values that are typically seen in treated patients have been described. Thus, “expected” trough and peak dabigatran plasma levels after intake of approved dosages for atrial fibrillation are around 61 to 143 and 117 to 275 ng/mL, respectively, for 150 mg twice a day and 43 to 102 and 85 to 200 ng/mL, respectively, for 110 mg twice a day.[4] Chin calculated an optimal trough range of 30 to 130 ng/mL after constructing a combined risk versus trough concentration model for a typical patient based on data from the RE-LY (Randomized Evaluation of Long-term anticoagulant therapY) trial.[1] [Table 1] shows the details of the four published case reports. Patients 1 and 2 had embolic stroke while taking dabigatran.[5] [6] Peak and trough plasma concentrations were measured thereafter using Hemoclot, a commercially available dilute thrombin time (dTT) assay, following witnessed intake. Patients 3 and 4 did not have thromboembolic events.[7] [8] Patient 3 had a lower than expected activated partial thromboplastin time (aPTT) shortly after starting dabigatran, so that peak concentrations at two dose levels were quantified, using Hemoclot, following confirmed intake after 31 days of treatment. Patient 4, who had undergone gastric bypass surgery, had trough concentrations quantified because another patient with gastric bypass developed a cardioembolic stroke on dabigatran and was found to have lower than expected aPTT values. The doses of dabigatran administered were appropriate for all four patients, especially after the dose increase in patient 3 who had normal renal function. The most likely contributors to concentrations below the within therapy range were obesity with glomerular hyperfiltration in patient 1 and major gastrointestinal surgery in patients 2 and 4. The documentation provided in the 12 additional reports that were not published is more limited. Nevertheless, together they add weight to the findings in the published reports and convey physicians' concerns. [Table 2] summarizes the 16 reports, published and unpublished. dTT assays were used to quantify plasma dabigatran in 12 reports. The method used was not stated in the remaining four. Two of these reported a concentration and the other two indicated that dabigatran was not detectable. Eight of the patients had cerebral or venous thromboembolic events, occurring between 3 and 270 days after starting dabigatran. Dabigatran concentrations were below the within therapy range or were too low to be quantified on the same day or shortly after the events while the patients were still taking dabigatran, two ([Table 1], patients 1 and 2) after witnessed administration. Of the patients who did not experience thromboembolic events, low concentrations were suspected and confirmed in two ([Table 1], patients 3 and 4). Three patients were found to have normal or lower than expected aPTTs, prior to cardioversion. Using a dTT method, dabigatran concentrations were found to be well below the expected within therapy trough level, with little difference when one patient continued dabigatran for a further 21 days. There was serious concern about cardioversion being delayed. The remaining three reports were submitted because each patient had undetectable peak and trough dabigatran concentrations measured by Hemoclot at 2 and 12 hours after witnessed intake. Duration of dabigatran use and the reason for measurement were not stated. Overall dabigatran concentrations ([Table 2]) were undetectable or below the expected trough range except for one peak level that was within the trough range at 50 ng/mL. Renal function is important in this context if there is glomerular hyperfiltration, as seen in [Table 1] (patient 1) or if a lower dose is used when renal function is normal. Four patients received the lower dose of 110 mg twice a day. One had a glomerular filtration rate of 37 to 43 mL/min and one ([Table 1], patient 3) did not achieve expected within therapy dabigatran concentrations when her dose was increased. Underdosing was a potential cause of low concentrations in the other two patients as their renal function was not recorded. [Table 2] shows the potential single and multiple contributors to subtherapeutic dabigatran concentrations. In six...


  • Open Access

    Erratum to: Impact of New Genomic Technologies on Understanding Adverse Drug Reactions

    by Simran D. S. Maggo, Ruth L. Savage, Martin A. Kennedy

  • Open Access

    Impact of New Genomic Technologies on Understanding Adverse Drug Reactions

    by Simran D. S. Maggo, Ruth L. Savage, Martin A. Kennedy

    It is well established that variations in genes can alter the pharmacokinetic and pharmacodynamic profile of a drug and immunological responses to it. Early advances in pharmacogenetics were made with traditional genetic techniques such as functional cloning of genes using knowledge gained from purified proteins, and candidate gene analysis. Over the past decade, techniques for analysing the human genome have accelerated greatly as knowledge and technological capabilities have grown. These techniques were initially focussed on understanding genetic factors of disease, but increasingly they are helping to clarify the genetic basis of variable drug responses and adverse drug reactions (ADRs). We examine genetic methods that have been applied to the understanding of ADRs, review the current state of knowledge of genetic factors that influence ADR development, and discuss how the application of genome-wide association studies and next-generation sequencing approaches is supporting and extending existing knowledge of pharmacogenetic processes leading to ADRs. Such approaches have identified single genes that are major contributing genetic risk factors for an ADR, (such as flucloxacillin and drug-induced liver disease), making pre-treatment testing a possibility. They have contributed to the identification of multiple genetic determinants of a single ADR, some involving both pharmacologic and immunological processes (such as phenytoin and severe cutaneous adverse reactions). They have indicated that rare genetic variants, often not previously reported, are likely to have more influence on the phenotype than common variants that have been traditionally tested for. The problem of genotype/phenotype discordance affecting the interpretation of pharmacogenetic screening and the future of genome-based testing applied to ADRs are also discussed.